Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Inclusion Criteria:

- Males or females with multiple myeloma who have exhausted available standard
therapies.

- Measurable disease, defined as any quantifiable monoclonal protein value

- ECOG performance-status score of 2 or less

- Life expectancy of at least 3 months

- Recovered from any previous surgery and no history of major surgery within the last 28
days prior to start of study drug

Exclusion Criteria:

- Any condition that, in the opinion of the Investigator, would interfere with
evaluation of the study drug or interpretation of subject safety or study results.

- Active infectious disease considered by the Investigator to be incompatible with the
protocol.

- Evidence of clinically significant cardiovascular and respiratory conditions

- Anti-myeloma treatment within 2 weeks

- Use of any investigational drug within the past 4 weeks